Spire Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Spire Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21	Closed	-$543	–	2369
2025 Q4	$543	Buy	+21	New	+$499	﹤0.01%	2282
2022 Q2	–	Sell	-500	Closed	-$38K	–	2793
2022 Q1	$38K	Buy	+500	New	+$33.3K	﹤0.01%	1552
2021 Q4	–	Sell	-100	Closed	-$6K	–	2985
2021 Q3	$6K	Sell	100 -500	-83%	-$28.8K	﹤0.01%	2245
2021 Q2	$36K	Hold	600	–	–	﹤0.01%	1631
2021 Q1	$42K	Buy	+600	New	+$42.9K	﹤0.01%	1817

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Spire Wealth Management's PCRX Position: Q1 2026 in Review

Spire Wealth Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 21 shares — an estimated $543 sold.

Spire Wealth Management first reported a position in PCRX in Q1 2021 and held it in 5 quarters. The position peaked at $42K in Q1 2021. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Spire Wealth Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Spire Wealth Management sold 21 Pacira BioSciences shares in Q1 2026, an estimated $543.
Spire Wealth Management first reported a position in Pacira BioSciences in Q1 2021 and held it in 5 quarters.
Spire Wealth Management's Pacira BioSciences position peaked at $42K in Q1 2021.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Spire Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.